Braeburn patents expiration
1. Brixadi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8545832 | BRAEBURN | Lipid depot formulations |
Jun, 2025
(1 year, 8 months from now) | |
| US8236755 | BRAEBURN | Opioid depot formulations |
Jul, 2026
(2 years from now) | |
| US8236292 | BRAEBURN | Liquid depot formulations |
Jan, 2027
(3 years from now) | |
| US10912772 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US9937164 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US11110084 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| US11135215 | BRAEBURN | Opioid formulations |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of delivery of a bioactive agent by subcutaneous injection. a method of treatment of a human for addiction; A method of delivery of an opioid bioactive agent. a method of treatment or prophyl...
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
More Information on Dosage
BRIXADI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic